CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Upgrades to OTCQB Venture Market
April 06, 2022 08:30 ET | Core One Labs Inc.
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Receives Positive Results from Bioassay Studies
April 02, 2022 08:55 ET | Core One Labs Inc.
VANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
March 15, 2022 04:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
March 03, 2022 03:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”), is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
February 21, 2022 16:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
February 10, 2022 03:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that,...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development
August 07, 2021 19:55 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 07, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion
August 05, 2021 01:15 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is a research and development...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021
July 30, 2021 03:10 ET | Core One Labs Inc.
VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP
July 26, 2021 07:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly...